Literature DB >> 25418579

Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.

Sonja Rothweiler1, Michael T Dill1, Luigi Terracciano2, Zuzanna Makowska1, Luca Quagliata2, Ruslan Hlushchuk3, Valentin Djonov3, Markus H Heim4, David Semela5.   

Abstract

Hepatic angiosarcoma (AS) is a rare and highly aggressive tumor of endothelial origin with dismal prognosis. Studies of the molecular biology of AS and treatment options are limited as animal models are rare. We have previously shown that inducible knockout of Notch1 in mice leads to spontaneous formation of hepatic AS. The aims of this study were to: (1) establish and characterize a cell line derived from this murine AS, (2) identify molecular pathways involved in the pathogenesis and potential therapeutic targets, and (3) generate a tumor transplantation model. AS cells retained specific endothelial properties such as tube formation activity, as well as expression of CD31 and Von Willebrand factor. However, electron microscopy analysis revealed signs of dedifferentiation with loss of fenestrae and loss of contact inhibition. Microarray and pathway analysis showed substantial changes in gene expression and revealed activation of the Myc pathway. Exposing the AS cells to sorafenib reduced migration, filopodia dynamics, and cell proliferation but did not induce apoptosis. In addition, sorafenib suppressed ERK phosphorylation and expression of cyclin D2. Injection of AS cells into NOD/SCID mice resulted in formation of undifferentiated tumors, confirming the tumorigenic potential of these cells. In summary, we established and characterized a murine model of spontaneous AS formation and hepatic AS cell lines as a useful in vitro tool. Our data demonstrate antitumor activity of sorafenib in AS cells with potent inhibition of migration, filopodia formation, and cell proliferation, supporting further evaluation of sorafenib as a novel treatment strategy. In addition, AS cell transplantation provides a subcutaneous tumor model useful for in vivo preclinical drug testing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25418579     DOI: 10.1038/labinvest.2014.141

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  34 in total

Review 1.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

2.  Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice.

Authors:  Michael T Dill; Sonja Rothweiler; Valentin Djonov; Ruslan Hlushchuk; Luigi Tornillo; Luigi Terracciano; Silvia Meili-Butz; Freddy Radtke; Markus H Heim; David Semela
Journal:  Gastroenterology       Date:  2012-01-12       Impact factor: 22.682

3.  Efficacy of Tie2 receptor antagonism in angiosarcoma.

Authors:  Jason R Hasenstein; Kelsey Kasmerchak; Darya Buehler; Gholam Reza Hafez; Kevin Cleary; John S Moody; Kevin R Kozak
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 4.  Malignant vascular tumors--an update.

Authors:  Cristina Antonescu
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

7.  Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1).

Authors:  M Masuzawa; T Fujimura; M Tsubokawa; S Nishiyama; K Katsuoka; E Terada; S Kunita; Y Sakurai; H Kato
Journal:  J Dermatol Sci       Date:  1998-01       Impact factor: 4.563

8.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Primary angiosarcomas of the breast.

Authors:  Taimur Sher; Bryan T Hennessy; Vicente Valero; Krisitine Broglio; Wendy A Woodward; Jonathan Trent; Kelly K Hunt; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

10.  NEW CYTOPLASMIC COMPONENTS IN ARTERIAL ENDOTHELIA.

Authors:  E R WEIBEL; G E PALADE
Journal:  J Cell Biol       Date:  1964-10       Impact factor: 10.539

View more
  7 in total

1.  Endothelial cell malignancies: new insights from the laboratory and clinic.

Authors:  Michael J Wagner; Vinod Ravi; David G Menter; Anil K Sood
Journal:  NPJ Precis Oncol       Date:  2017-04-20

2.  Diethylnitrosamine (DENA) recapitulates formation of hepatic angiosarcoma in pigs.

Authors:  Sonja M Kessler; Bettina Leber; Jessica Hoppstädter; Nicole Golob-Schwarzl; Eva M Hofer; Christina S Schultheiss; Hans-Jörg Mischinger; Bernadette Liegl-Atzwanger; Carolin Lackner; Philipp Stiegler; Johannes Haybaeck
Journal:  PLoS One       Date:  2019-05-16       Impact factor: 3.240

3.  Combined VEGFR and MAPK pathway inhibition in angiosarcoma.

Authors:  Michael J Wagner; Yasmin A Lyons; Jean H Siedel; Robert Dood; Archana S Nagaraja; Monika Haemmerle; Lingegowda S Mangala; Pritha Chanana; Alexander J Lazar; Wei-Lien Wang; Vinod Ravi; Eric C Holland; Anil K Sood
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

4.  HOXA Amplification Defines a Genetically Distinct Subset of Angiosarcomas.

Authors:  Hongbo M Xie; Kathrin M Bernt
Journal:  Biomolecules       Date:  2022-08-16

5.  Extracellular matrix composition modulates angiosarcoma cell attachment and proliferation.

Authors:  Noel L Shaheen; Esha Kataria; Jocelyn Antony; Dana Galvan; Yessenia Ballou; Brad A Bryan
Journal:  Oncoscience       Date:  2017-12-07

6.  Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma.

Authors:  V Konduri; M M Halpert; L Douglass; W K Decker; Y C Baig; R Coronado; J R Rodgers; J M Levitt; B Cerroni; S Piscoya; N Wilson; L DiBernardi; Z Omarbekov; L Seelhoff; V Ravi
Journal:  Cancer Gene Ther       Date:  2019-01-23       Impact factor: 5.987

Review 7.  Animal Modeling of Pediatric Liver Cancer.

Authors:  Richard S Whitlock; Tianyou Yang; Sanjeev A Vasudevan; Sarah E Woodfield
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.